Omnicell, Inc. (OMCL)

Over the past six months, Omnicell's stock has trended up. Q4 2025 earnings release showed revenues met expectations, but profit per share was below estimates, leading to a negative market reaction. The launch of Titan XT is expected to drive hardware replacement. The acquisition of ANiGENT enhances drug diversion detection capabilities. Q3 2025 earnings showed strong financial performance, exceeding guidance.

The provided information does not explicitly detail demand seasonality for Omnicell, Inc.'s products and services. However, the company's strategic shift towards a software and services-led model and an increase in recurring revenue streams suggests a move away from strong seasonality that might be associated with purely transactional hardware sales.

Omnicell, Inc. is a healthcare technology company providing medication management solutions and adherence tools. Its core business transforms pharmacy and nursing care delivery through innovation. Major products include automated dispensing systems, central pharmacy automation solutions, medication adherence solutions, intelligent software and services, and specialty pharmacy services. The company is advancing its vision of the Autonomous Pharmacy, integrating AI, analytics, and SaaS models.

Omnicell has a global presence with its headquarters in Fort Worth, Texas. It operates primarily in North America, with expanding footprints in Europe and Asia-Pacific. International offices are located in Australia, China, France, Germany, India, Italy, Netherlands, United Arab Emirates, and the United Kingdom. In the United States, Omnicell has offices in multiple cities in addition to its headquarters.

Omnicell maintains a positive brand reputation within the healthcare technology sector. The company was recognized as one of the Top 50 Healthcare Technology Companies. The CEO, Randall Lipps, was named one of the Top Healthcare Technology CEOs of 2025. Omnicell actively participates in key industry events.

Omnicell, Inc. is predominantly owned by institutional investors such as BlackRock, Inc. and Vanguard Group Inc. Randall A. Lipps, the company's founder, chairman, president, and CEO, is the largest individual shareholder.